Back to Index
David I Quinn, MD
Associate Professor of Medicine (Clinical Scholar)
Section Head, Genitourinary (Gu) Oncology, Division of Cancer Medicine and Blood Diseases in The Department of Medicine
NOR 3453 Health Sciences Campus Los Angeles
+1 323 865 3956


David Ian Quinn MBBS Honors Class I, PhD, FRACP FACP is an international expert in the field of clinical trials and molecular correlative studies in genitourinary cancer. Dr. Quinn is the medical director of the Norris Cancer Hospital and Clinics, head of the Section of Genitourinary Medical Oncology and associate professor of Medicine in the Division of Cancer Medicine and Blood Diseases at the Keck School of Medicine of USC. Prior experience includes Directorship of the Clinical Investigation Support Office and Leadership of the Genitourinary Cancer and Developmental Therapeutics Programs for the USC Norris Comprehensive Cancer Center.

He is a medical oncologist with focus in the field of clinical trials and molecular correlative studies in genitourinary cancer and early therapeutics. David Quinn has published more than 100 papers, reviews and chapters including recent publications in the journals Cancer Research, Clinical Cancer Research, Oncogene, Proceedings of the National Academy of Science, Journal of the National Cancer Institute, Lancet Oncology, New England Journal of Medicine and Journal of Clinical Oncology. Dr. Quinn is a reviewer for more than 50 peer-reviewed journals and is on the editorial boards of is on the editorial boards of American Journal of Clinical Oncology, cancer.net (American Society of Clinical Oncology), Clinical Genitourinary Cancer, Bladder Cancer and Annals of Oncology. Dr. Quinn is a member of the NCI Renal Cancer Task Force, Co-Chair for Genitourinary Cancer in the California Cancer Consortium and is SWOG organ site chair for advanced prostate cancer. He is a full member of the Department of Defense Integration Panel for Prostate Cancer Awards and has been an invited speaker in more than 40 countries.

Dr. Quinn's current focus is on clinical trials and translation applications at USC and with SWOG and the California Cancer Consortium, where he has been principal investigator on more than 100 clinical trials for locally advanced and castrate-resistant prostate cancer, high grade urothelial cancer, advanced renal cell cancer, refractory germ cell tumors and adrenocortical carcinoma.


University of New South Wales: Gordon Lowe Memorial Prize, 1987

USC Norris Cancer Center and Hospital: The Spirit of Norris Award, 2002

Postgraduate Medical Council of New South Wales: Distinguished Contribution Award, 2000

University of New South Wales: Honours First Class Bachelor of Medicine, Bachelor of Surgery, 1987

National Health and Medical Research Council of Australia: Neil Hamilton Fairley Fellowship, 2000-2003

National Health and Medical Research Council of Australia: Postgraduate Medical Scholarship, 1996-1999

Castle Connolly Medical: America's Top Doctors, 2010

Royal Australasian College of Physicians: Vincent Fairfax Family Fellowship, 2001

St. Vincent's Clinic Foundation: The David Wilson Travelling Fellowship, 2000


Feldman DR, Hu J, Dorff TB, Lim K, Patil S, Woo KM, Carousso M, Hughes A, Sheinfeld J, Bains M, Daneshmand S, Ketchens C, Bajorin DF, Bosl GJ, Quinn DI, Motzer RJ. Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. J Clin Oncol. 2016 Jul 20; 34(21):2478-83. View in: PubMed

Halabi S, Kelly WK, Ma H, Zhou H, Solomon NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP, Hussain M, Vogelzang NJ, Thompson IM, Chi KN, de Bono J, Armstrong AJ, Eisenberger MA, Fandi A, Li S, Araujo JC, Logothetis CJ, Quinn DI, Morris MJ, Higano CS, Tannock IF, Small EJ. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016 May 10; 34(14):1652-9. View in: PubMed

Hu BR, Fairey AS, Madhav A, Yang D, Li M, Groshen S, Stephens C, Kim PH, Virk N, Wang L, Martin SE, Erho N, Davicioni E, Jenkins RB, Den RB, Xu T, Xu Y, Gill IS, Quinn DI, Goldkorn A. AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate. 2016 May; 76(6):597-608. View in: PubMed

Petrylak DP, Tagawa ST, Kohli M, Eisen A, Canil C, Sridhar SS, Spira A, Yu EY, Burke JM, Shaffer D, Pan CX, Kim JJ, Aragon-Ching JB, Quinn DI, Vogelzang NJ, Tang S, Zhang H, Cavanaugh CT, Gao L, Kauh JS, Walgren RA, Chi KN. Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. J Clin Oncol. 2016 May 1; 34(13):1500-9. View in: PubMed

Wu Y, Chen YX, Yan J, Quinn D, Dong P, Sawyer SW, Soman P. Fabrication of conductive gelatin methacrylate-polyaniline hydrogels. Acta Biomater. 2016 Mar 15; 33:122-30. View in: PubMed

Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, Cheng CW, Brandhorst S, Cohen P, Wei M, Longo V, Quinn DI. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016; 16(1):360. View in: PubMed

Quinn DI, Lara PN. Renal-Cell Cancer--Targeting an Immune Checkpoint or Multiple Kinases. N Engl J Med. 2015 Nov 5; 373(19):1872-4. View in: PubMed

Morgan RJ, Synold TW, Longmate JA, Quinn DI, Gandara D, Lenz HJ, Ruel C, Xi B, Lewis MD, Colevas AD, Doroshow J, Newman EM. Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. Cancer Chemother Pharmacol. 2015 Nov; 76(5):897-907. View in: PubMed

Quinn D, Frith D. Assessing the damage control resuscitation: Development, drivers and direction. Emerg Med Australas. 2015 Oct; 27(5):485-7. View in: PubMed

Dorff TB, Hu J, Quinn DI. Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urol Oncol. 2015 Aug; 33(8):341-2. View in: PubMed

Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M, Gill IS. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. J Urol. 2015 Aug; 194(2):378-85. View in: PubMed

Jadvar H, Challa S, Quinn DI, Conti PS. One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. Cancer Biother Radiopharm. 2015 Jun; 30(5):195-9. View in: PubMed

Yu EY, Li H, Higano CS, Agarwal N, Pal SK, Alva A, Heath EI, Lam ET, Gupta S, Lilly MB, Inoue Y, Chi KN, Vogelzang NJ, Quinn DI, Cheng HH, Plymate SR, Hussain M, Tangen CM, Thompson IM. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2015 May 10; 33(14):1601-8. View in: PubMed

Quinn DI, Shore ND, Egawa S, Gerritsen WR, Fizazi K. Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. Urol Oncol. 2015 May; 33(5):245-60. View in: PubMed

Goldkorn A, Ely B, Tangen CM, Tai YC, Xu T, Li H, Twardowski P, Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Vogelzang NJ, Thompson IM, Cote RJ, Quinn DI. Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: A phase III metastatic castration resistant prostate cancer trial. Int J Cancer. 2015 Apr 15; 136(8):1856-62. View in: PubMed

Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr; 16(4):426-35. View in: PubMed

Rini BI, Quinn DI, Baum M, Wood LS, Tarazi J, Rosbrook B, Arruda LS, Cisar L, Roberts WG, Kim S, Motzer RJ. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. Target Oncol. 2015 Mar; 10(1):45-53. View in: PubMed

Jadvar H, Groshen SG, Quinn DI. Association of overall survival with glycolytic activity of castrate-resistant prostate cancer metastases. Radiology. 2015 Feb; 274(2):624-5. View in: PubMed

Liu SV, Tsao-Wei DD, Xiong S, Groshen S, Dorff TB, Quinn DI, Tai YC, Engel J, Hawes D, Schally AV, Pinski JK. Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. Clin Cancer Res. 2014 Dec 15; 20(24):6277-83. View in: PubMed

Ballas LK, Hu BR, Quinn DI. Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncol. 2014 Dec; 15(13):1419-21. View in: PubMed

Alpert BS, Quinn D, Gallick D. Oscillometric blood pressure: a review for clinicians. J Am Soc Hypertens. 2014 Dec; 8(12):930-8. View in: PubMed

Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry AB, Pham HQ, Roman L, Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. View in: PubMed

Milowsky MI, Dittrich C, Durán I, Jagdev S, Millard FE, Sweeney CJ, Bajorin D, Cerbone L, Quinn DI, Stadler WM, Rosenberg JE, Lochheed M, Sen P, Squires M, Shi M, Sternberg CN. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. Eur J Cancer. 2014 Dec; 50(18):3145-52. View in: PubMed

Hussain M, Daignault S, Agarwal N, Grivas PD, Siefker-Radtke AO, Puzanov I, MacVicar GR, Levine EG, Srinivas S, Twardowski P, Eisenberger MA, Quinn DI, Vaishampayan UN, Yu EY, Dawsey S, Day KC, Day ML, Al-Hawary M, Smith DC. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer. 2014 Sep 1; 120(17):2684-93. View in: PubMed

Apolo AB, Kim JW, Bochner BH, Steinberg SM, Bajorin DF, Kevin Kelly W, Agarwal PK, Koppie TM, Kaag MG, Quinn DI, Vogelzang NJ, Sridhar SS. Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Urol Oncol. 2014 Jul; 32(5):637-44. View in: PubMed

Cheng CW, Adams GB, Perin L, Wei M, Zhou X, Lam BS, Da Sacco S, Mirisola M, Quinn DI, Dorff TB, Kopchick JJ, Longo VD. Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression. Cell Stem Cell. 2014 Jun 5; 14(6):810-23. View in: PubMed

Dorff TB, Hu JS, Quinn DI. Salvage chemotherapy for refractory germ cell tumors. Oncology (Williston Park). 2014 Jun; 28(6):498-500. View in: PubMed

Quinn D. Skate park injury: A new mechanism of sternoclavicular joint dislocation. Emerg Med Australas. 2014 Jun; 26(3):316-7. View in: PubMed

Goldkorn A, Ely B, Quinn DI, Tangen CM, Fink LM, Xu T, Twardowski P, Van Veldhuizen PJ, Agarwal N, Carducci MA, Monk JP, Datar RH, Garzotto M, Mack PC, Lara P, Higano CS, Hussain M, Thompson IM, Cote RJ, Vogelzang NJ. Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol. 2014 Apr 10; 32(11):1136-42. View in: PubMed

Dart RA, Alpert B, Quinn D. Effect of mechanical behavior of the brachial artery on blood pressure measurement during cuff inflation and cuff deflation. Blood Press Monit. 2014 Apr; 19(2):120. View in: PubMed

Dorff TB, Wilkins C, Hepgur M, Quinn DI. Durable complete remission from castration-resistant prostate cancer with sipuleucel-T after estrogen withdrawal. Clin Genitourin Cancer. 2014 Apr; 12(2):e55-8. View in: PubMed

Lara PN, Ely B, Quinn DI, Mack PC, Tangen C, Gertz E, Twardowski PW, Goldkorn A, Hussain M, Vogelzang NJ, Thompson IM, Van Loan MD. Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421. J Natl Cancer Inst. 2014 Apr 1; 106(4):dju013. View in: PubMed

Vashistha V, Quinn DI, Dorff TB, Daneshmand S. Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. BMC Cancer. 2014; 14:966. View in: PubMed

Li X, Choi WW, Yan R, Yu H, Krasnoperov V, Kumar SR, Schuckman A, Klumpp DJ, Pan CX, Quinn D, Gill IS, Gill PS, Liu R. The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder. PLoS One. 2014; 9(8):e105326. View in: PubMed

Bhatia S, Curti B, Ernstoff MS, Gordon M, Heath EI, Miller WH, Puzanov I, Quinn DI, Flaig TW, VanVeldhuizen P, Byrnes-Blake K, Freeman JA, Bittner R, Hunder N, Souza S, Thompson JA. Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. J Immunother Cancer. 2014; 2:2. View in: PubMed

Quinn DI, Vaishampayan U, Higano CS, Lin DW, Shore ND, Beer TM. Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Rev Anticancer Ther. 2014 Jan; 14(1):51-61. View in: PubMed

Dorff TB, Pal SK, Quinn DI. Novel tyrosine kinase inhibitors for renal cell carcinoma. Expert Rev Clin Pharmacol. 2014 Jan; 7(1):67-73. View in: PubMed

Mitra AP, Skinner EC, Schuckman AK, Quinn DI, Dorff TB, Daneshmand S. Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. Urol Oncol. 2014 Jan; 32(1):52. e1-9. View in: PubMed

Brown A, Ma Y, Danenberg K, Schuckman AK, Pinski JK, Pagliaro LC, Quinn DI, Dorff TB. Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases. Urology. 2014 Jan; 83(1):159-66. View in: PubMed

Dorff TB, Tsao-Wei DD, Groshen S, Boswell W, Goldkorn A, Xiong S, Quinn DI, Pinski JK. Efficacy of oxaliplatin plus pemetrexed in chemotherapy pretreated metastatic castration-resistant prostate cancer. Clin Genitourin Cancer. 2013 Dec; 11(4):416-22. View in: PubMed

Jadvar H, Quinn DI. Targeted a-Particle Therapy of Bone Metastases in Prostate Cancer. Clin Nucl Med. 2013 Dec; 38(12):966-71. View in: PubMed

Pal SK, Quinn DI. Differentiating mTOR inhibitors in renal cell carcinoma. Cancer Treat Rev. 2013 Nov; 39(7):709-19. View in: PubMed

Fairey AS, Daneshmand S, Quinn D, Dorff T, Dorin R, Lieskovsky G, Schuckman A, Cai J, Miranda G, Skinner EC. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urol Oncol. 2013 Nov; 31(8):1737-43. View in: PubMed

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Pinski JK, Quinn DI. Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer. J Nucl Med. 2013 Aug; 54(8):1195-201. View in: PubMed

Feldman DR, Einhorn LH, Quinn DI, Loriot Y, Joffe JK, Vaughn DJ, Fléchon A, Hajdenberg J, Halim AB, Zahir H, Motzer RJ. A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. Invest New Drugs. 2013 Aug; 31(4):1016-22. View in: PubMed

Quinn DI, Tangen CM, Hussain M, Lara PN, Goldkorn A, Moinpour CM, Garzotto MG, Mack PC, Carducci MA, Monk JP, Twardowski PW, Van Veldhuizen PJ, Agarwal N, Higano CS, Vogelzang NJ, Thompson IM. Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol. 2013 Aug; 14(9):893-900. View in: PubMed

Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4; 368(14):1314-25. View in: PubMed

Hepgur M, Sadeghi S, Dorff TB, Quinn DI. Tivozanib in the treatment of renal cell carcinoma. Biologics. 2013; 7:139-48. View in: PubMed

Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2013 Jan 1; 31(1):131-61. View in: PubMed

Sternberg CN, Bellmunt J, Sonpavde G, Siefker-Radtke AO, Stadler WM, Bajorin DF, Dreicer R, George DJ, Milowsky MI, Theodorescu D, Vaughn DJ, Galsky MD, Soloway MS, Quinn DI. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings. Eur Urol. 2013 Jan; 63(1):58-66. View in: PubMed

Eisen T, Joensuu H, Nathan PD, Harper PG, Wojtukiewicz MZ, Nicholson S, Bahl A, Tomczak P, Pyrhonen S, Fife K, Bono P, Boxall J, Wagner A, Jeffers M, Lin T, Quinn DI. Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. Lancet Oncol. 2012 Oct; 13(10):1055-62. View in: PubMed

Fahed E, Hansel DE, Raghavan D, Quinn DI, Dorff TB. Small cell bladder cancer: biology and management. Semin Oncol. 2012 Oct; 39(5):615-8. View in: PubMed

Kindler HL, Karrison TG, Gandara DR, Lu C, Krug LM, Stevenson JP, Jänne PA, Quinn DI, Koczywas MN, Brahmer JR, Albain KS, Taber DA, Armato SG, Vogelzang NJ, Chen HX, Stadler WM, Vokes EE. Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. J Clin Oncol. 2012 Jul 10; 30(20):2509-15. View in: PubMed

Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross ME, Pinski JK, Quinn DI. Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. View in: PubMed

Zhang SY, Thara E, Quinn D, Dorff T. Blood cells and their use in active immunotherapy of prostate cancer. Hum Vaccin Immunother. 2012 Apr 1; 8(4):528-33. View in: PubMed

Pal SK, Williams S, Josephson DY, Carmichael C, Vogelzang NJ, Quinn DI. Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm. Mol Cancer Ther. 2012 Mar; 11(3):526-37. View in: PubMed

Mitra AP, Quinn DI, Dorff TB, Skinner EC, Schuckman AK, Miranda G, Gill IS, Daneshmand S. Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. BJU Int. 2012 Mar; 109(6):846-54. View in: PubMed

Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY, Quinn DI, Hahn NM, Hutson TE, Sonpavde G, Morrissey SC, Buckle GC, Kim WY, Petrylak DP, Ryan CW, Eisenberger MA, Mortazavi A, Bubley GJ, Taplin ME, Rosenberg JE, Kantoff PW. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012 Feb 10; 30(5):507-12. View in: PubMed

Thara E, Dorff TB, Averia-Suboc M, Luther M, Reed ME, Pinski JK, Quinn DI. Immune response to sipuleucel-T in prostate cancer. Cancers (Basel). 2012; 4(2):420-41. View in: PubMed

Armstrong AJ, Ferrari AC, Quinn DI. The role of surrogate markers in the management of men with metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2011 Dec; 9(12 Suppl 28):1-14; quiz 15-6. View in: PubMed

Shek D, Longmate J, Quinn DI, Margolin KA, Twardowski P, Gandara DR, Frankel P, Pan CX, Lara PN. A phase II trial of gefitinib and pegylated IFNa in previously treated renal cell carcinoma. Int J Clin Oncol. 2011 Oct; 16(5):494-9. View in: PubMed

Desai B, Elatre W, Quinn DI, Jadvar H. FDG PET/CT demonstration of pancreatic metastasis from prostate cancer. Clin Nucl Med. 2011 Oct; 36(10):961-2. View in: PubMed

Thara E, Dorff TB, Pinski JK, Quinn DI. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011 Aug; 69(4):296-303. View in: PubMed

Bellmunt J, Eisen T, Fishman M, Quinn D. Experience with sorafenib and adverse event management. Crit Rev Oncol Hematol. 2011 Apr; 78(1):24-32. View in: PubMed

Quinn D, Gross M. Show us a sign: the search for "game changing" prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6. View in: PubMed

Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. View in: PubMed

Ell K, Xie B, Kapetanovic S, Quinn DI, Lee PJ, Wells A, Chou CP. One-year follow-up of collaborative depression care for low-income, predominantly Hispanic patients with cancer. Psychiatr Serv. 2011 Feb; 62(2):162-70. View in: PubMed

Swanson GP, Quinn D. Using molecular markers to help predict who will fail after radical prostatectomy. Prostate Cancer. 2011; 2011:290160. View in: PubMed

Dorff TB, Quinn DI. Cabazitaxel in prostate cancer: stretching a string. Lancet. 2010 Oct 2; 376(9747):1119-20. View in: PubMed

Twardowski P, Stadler WM, Frankel P, Lara PN, Ruel C, Chatta G, Heath E, Quinn DI, Gandara DR. Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology. 2010 Oct; 76(4):923-6. View in: PubMed

Dorff TB, Goldman B, Pinski JK, Mack PC, Lara PN, Van Veldhuizen PJ, Quinn DI, Vogelzang NJ, Thompson IM, Hussain MH. Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res. 2010 Jun 1; 16(11):3028-34. View in: PubMed

Bellmunt J, Fishman M, Eisen T, Quinn D. Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther. 2010 Jun; 10(6):825-35. View in: PubMed

Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 1; 27(34):5788-93. View in: PubMed

Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, Cohen P, Longo VD. Fasting and cancer treatment in humans: A case series report. Aging (Albany NY). 2009 Dec; 1(12):988-1007. View in: PubMed

Dorff TB, Quinn DI. Perioperative chemotherapy for urothelial cancer: how have we made a "sow's ear" out of a chemotherapy-sensitive tumor? Cancer. 2009 Nov 15; 115(22):5139-42. View in: PubMed

Dorff TB, Goldkorn A, Quinn DI. Targeted therapy in renal cancer. Ther Adv Med Oncol. 2009 Nov; 1(3):183-205. View in: PubMed

Lara PN, Longmate J, Evans CP, Quinn DI, Twardowski P, Chatta G, Posadas E, Stadler W, Gandara DR. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs. 2009 Mar; 20(3):179-84. View in: PubMed

Dorff TB, Tsao-Wei D, Miranda G, Skinner DG, Stein JP, Quinn DI. Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. World J Urol. 2009 Feb; 27(1):39-44. View in: PubMed

Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, Acharya M, Chan K, Cohen N, Dudov A. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet. 2009; 48(3):199-209. View in: PubMed

Cheung E, Pinski J, Dorff T, Groshen S, Quinn DI, Reynolds CP, Maurer BJ, Lara PN, Tsao-Wei DD, Twardowski P, Chatta G, McNamara M, Gandara DR. Oral fenretinide in biochemically recurrent prostate cancer: a California cancer consortium phase II trial. Clin Genitourin Cancer. 2009 Jan; 7(1):43-50. View in: PubMed

Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW. A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. BJU Int. 2008 Dec; 102(11):1601-6. View in: PubMed

Smith DC, Mackler NJ, Dunn RL, Hussain M, Wood D, Lee CT, Sanda M, Vaishampayan U, Petrylak DP, Quinn DI, Beekman K, Montie JE. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J Urol. 2008 Dec; 180(6):2384-8; discussion 2388. View in: PubMed

Tagawa ST, Dorff TB, Rochanda L, Ye W, Boyle S, Raghavan D, Lieskovsky G, Skinner DG, Quinn DI, Liebman HA. Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int. 2008 Nov; 102(9):1086-91. View in: PubMed

Ell K, Xie B, Quon B, Quinn DI, Dwight-Johnson M, Lee PJ. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol. 2008 Sep 20; 26(27):4488-96. View in: PubMed

Stadler WM, Desai AA, Quinn DI, Bukowski R, Poiesz B, Kardinal CG, Lewis N, Makalinao A, Murray P, Torti FM. A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. Cancer Chemother Pharmacol. 2008 Apr; 61(4):689-94. View in: PubMed

Chee KG, Longmate J, Quinn DI, Chatta G, Pinski J, Twardowski P, Pan CX, Cambio A, Evans CP, Gandara DR, Lara PN. The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. Clin Genitourin Cancer. 2007 Dec; 5(7):433-7. View in: PubMed

Margolin K, Synold TW, Lara P, Frankel P, Lacey SF, Quinn DI, Baratta T, Dutcher JP, Xi B, Diamond DJ, Gandara DR. Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. J Cancer Res Clin Oncol. 2007 Oct; 133(10):705-11. View in: PubMed

Turner JS, Cheung EM, George J, Quinn DI. Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU Int. 2007 May; 99(5 Pt B):1305-12. View in: PubMed

Ell K, Quon B, Quinn DI, Dwight-Johnson M, Wells A, Lee PJ, Xie B. Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. Gen Hosp Psychiatry. 2007 May-Jun; 29(3):223-31. View in: PubMed

Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD, Biankin AV, Kench JG, Sutherland RL. Zinc-alpha2-glycoprotein expression as a predictor of metastatic prostate cancer following radical prostatectomy. J Natl Cancer Inst. 2006 Oct 4; 98(19):1420-4. View in: PubMed

Beer TM, Tangen CM, Nichols CR, Margolin KA, Dreicer R, Stephenson WT, Quinn DI, Raghavan D, Crawford ED. Southwest Oncology Group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. Cancer. 2006 Jun 15; 106(12):2624-9. View in: PubMed

Levine AM, Tulpule A, Quinn DI, Gorospe G, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy. J Clin Oncol. 2006 Apr 10; 24(11):1712-9. View in: PubMed

Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L, Groshen S, Zhu S, Masood R, Quinn DI, Broek D, Stein JP, Gill PS. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol. 2006 Apr; 175(4):1245-52. View in: PubMed

Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases. Clin Cancer Res. 2006 Mar 1; 12(5):1556-63. View in: PubMed

Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. J Thorac Oncol. 2006 Feb; 1(2):126-34. View in: PubMed

Garcia AA, Iqbal S, Quinn D, Edwards S, Lenz HJ, Weber J. Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. Invest New Drugs. 2006 Jan; 24(1):79-83. View in: PubMed

Hutson TE, Quinn DI. Cytokine therapy: a standard of care for metastatic renal cell carcinoma? Clin Genitourin Cancer. 2005 Dec; 4(3):181-6. View in: PubMed

Quek ML, Simma-Chiang V, Stein JP, Pinski J, Quinn DI, Skinner DG. Postchemotherapy residual masses in advanced seminoma: current management and outcomes. Expert Rev Anticancer Ther. 2005 Oct; 5(5):869-74. View in: PubMed

Plasencia C, Dayam R, Wang Q, Pinski J, Burke TR, Quinn DI, Neamati N. Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. Mol Cancer Ther. 2005 Jul; 4(7):1105-13. View in: PubMed

Xia G, Kumar SR, Masood R, Koss M, Templeman C, Quinn D, Zhu S, Reddy R, Krasnoperov V, Gill PS. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin Cancer Res. 2005 Jun 15; 11(12):4305-15. View in: PubMed

Xia G, Kumar SR, Masood R, Zhu S, Reddy R, Krasnoperov V, Quinn DI, Henshall SM, Sutherland RL, Pinski JK, Daneshmand S, Buscarini M, Stein JP, Zhong C, Broek D, Roy-Burman P, Gill PS. EphB4 expression and biological significance in prostate cancer. Cancer Res. 2005 Jun 1; 65(11):4623-32. View in: PubMed

Aparicio AM, Elkhouiery AB, Quinn DI. The current and future application of adjuvant systemic chemotherapy in patients with bladder cancer following cystectomy. Urol Clin North Am. 2005 May; 32(2):217-30, vii. View in: PubMed

Quinn DI, Henshall SM, Sutherland RL. Molecular markers of prostate cancer outcome. Eur J Cancer. 2005 Apr; 41(6):858-87. View in: PubMed

Buscarini M, Quek ML, Gill P, Xia G, Quinn DI, Stein JP. Molecular prognostic factors in bladder cancer. BJU Int. 2005 Apr; 95(6):739-42. View in: PubMed

Lara PN, Twardowski P, Quinn DI. Angiogenesis-targeted therapies in prostate cancer. Clin Prostate Cancer. 2004 Dec; 3(3):165-73. View in: PubMed

Newell ME, Hoy JF, Cooper SG, DeGraaff B, Grulich AE, Bryant M, Millar JL, Brew BJ, Quinn DI. Human immunodeficiency virus-related primary central nervous system lymphoma: factors influencing survival in 111 patients. Cancer. 2004 Jun 15; 100(12):2627-36. View in: PubMed

Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Cote RJ, Lieskovsky G, Quinn DI, Skinner DG. Microscopic and gross extravesical extension in pathological staging of bladder cancer. J Urol. 2004 Feb; 171(2 Pt 1):640-5. View in: PubMed

Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer PG, Erbersdobler A, Schroeder F, Wildhagen M, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. Is year of radical prostatectomy a predictor of outcome in prostate cancer? J Urol. 2004 Feb; 171(2 Pt 1):692-6. View in: PubMed

Quinn DI. The future in advanced prostate cancer: take your partners or is the last dance for me? Rev Urol. 2004; 6 Suppl 10:S29-44. View in: PubMed

Cagiannos I, Karakiewicz P, Eastham JA, Ohori M, Rabbani F, Gerigk C, Reuter V, Graefen M, Hammerer PG, Erbersdobler A, Huland H, Kupelian P, Klein E, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol. 2003 Nov; 170(5):1798-803. View in: PubMed

Lara PN, Quinn DI, Margolin K, Meyers FJ, Longmate J, Frankel P, Mack PC, Turrell C, Valk P, Rao J, Buckley P, Wun T, Gosselin R, Galvin I, Gumerlock PH, Lenz HJ, Doroshow JH, Gandara DR. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition. Clin Cancer Res. 2003 Oct 15; 9(13):4772-81. View in: PubMed

Henshall SM, Afar DE, Rasiah KK, Horvath LG, Gish K, Caras I, Ramakrishnan V, Wong M, Jeffry U, Kench JG, Quinn DI, Turner JJ, Delprado W, Lee CS, Golovsky D, Brenner PC, O'Neill GF, Kooner R, Stricker PD, Grygiel JJ, Mack DH, Sutherland RL. Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. Oncogene. 2003 Sep 4; 22(38):6005-12. View in: PubMed

Quek ML, Stein JP, Clark PE, Daneshmand S, Miranda G, Cai J, Groshen S, Lieskovsky G, Quinn DI, Raghavan D, Skinner DG. Natural history of surgically treated bladder carcinoma with extravesical tumor extension. Cancer. 2003 Sep 1; 98(5):955-61. View in: PubMed

Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res. 2003 Jul 15; 63(14):4196-203. View in: PubMed

Quinn DI, Henshall SM, Brenner PC, Kooner R, Golovsky D, O'Neill GF, Turner JJ, Delprado W, Grygiel JJ, Sutherland RL, Stricker PD. Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy: importance of percentage of biopsies that contain tumor and the presence of biopsy perineural invasion. Cancer. 2003 Apr 15; 97(8):1884-93. View in: PubMed

Welsh JB, Sapinoso LM, Kern SG, Brown DA, Liu T, Bauskin AR, Ward RL, Hawkins NJ, Quinn DI, Russell PJ, Sutherland RL, Breit SN, Moskaluk CA, Frierson HF, Hampton GM. Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A. 2003 Mar 18; 100(6):3410-5. View in: PubMed

Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002 Aug 1; 20(15):3206-12. View in: PubMed

Raghavan D, Quinn D, Skinner DG, Stein JP. Surgery and adjunctive chemotherapy for invasive bladder cancer. Surg Oncol. 2002 Jun; 11(1-2):55-63. View in: PubMed

Graefen M, Karakiewicz PI, Cagiannos I, Klein E, Kupelian PA, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, Scardino PT, Kattan MW. Validation study of the accuracy of a postoperative nomogram for recurrence after radical prostatectomy for localized prostate cancer. J Clin Oncol. 2002 Feb 15; 20(4):951-6. View in: PubMed

Powered bySC CTSI